EYE ASX Week ended 31 Jul 2026

Weekly Investor Report

Name: EYE weekly investor report
Creator: Sharemaestro
License: https://sharemaestro.com/data-license/

Nova Eye Medical Limited · Healthcare · Medical Devices

Open interactive chart View report data

Latest close 0.13 AUD

4.0% latest week

Weekly setup

Mixed setup

The weekly trend is not active. Price is -3.8% below the Trend Line and sits at 28.6% of its 52-week range. The latest completed week returned 4.0%, after a 23.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 52/100.

Setup score 46 out of 100

Latest Close 0.13 AUD 31 Jul 2026

1W Return 4.0% latest completed week

4W Return 23.8% short-term follow-through

12W Return 2.0% quarterly tape

Trend Breadth 44.2% 23 of 52 weeks active

Volume Ratio 2.2x vs 13-week average

What is working

Activity pressure is positive on the latest completed week.
Volume is elevated versus the 13-week average, confirming attention.

What could go wrong

The trend backdrop is inactive, so price action has not confirmed a constructive regime.
Price is below the Trend Line, which keeps downside pressure in focus.
Price is below Fair Value, so the market is still discounting the latest tape.
Next-week expectancy is negative at 38.04% based on similar historical setup states.

What to watch next

Trend Line remains the key weekly regime level.
Activity pressure is the gauge to monitor for confirmation or fade.
A volume ratio above 1.5x would show stronger participation in the next move.

Price follow-through 4.0% Latest completed week; four-week move 23.8%. Indicator stack 24/68 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Buy Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 38.04% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 52/100 35 relevant articles in the latest sentiment read.

01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -3.8% below the Trend Line and sits at 28.6% of its 52-week range. The latest completed week returned 4.0%, after a 23.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value

Price Trend Line Fair Value

Position in the 52-week range

Close Trend Fair

0.10 AUD 28.6% 0.20 AUD

Range location28.6%Shows where the latest close sits between the 52-week low and high.

Trend distance-3.8%Price premium or discount versus the weekly Trend Line.

Fair-value gap-23.1%Premium demand or model discount versus Sharemaestro Fair Value.

High-water gap-36.6%Distance from the latest 52-week high.

02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction

6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul

Up week Down week

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0512-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.

Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.

Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.

Activity pressure0.05Current proprietary activity-pressure read.

Buy signals1Accumulation signal count in the latest 12 weeks.

Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 23.8% over four weeks, 2.0% over 12 weeks, and -10.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.0%

4W23.8%

12W2.0%

26W-29.7%

52W-10.3%

Active trend streak0 weeks

Active weeks in one year23

Trend breadth44.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership

Pressure0.40Latest activity-pressure read.

Pressure change137.1%Four-week change in activity pressure.

Leadership-8.14Latest relative-leadership reading.

RS change68.0%Four-week change in relative leadership.

04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis

Factor week 26 Jul 2026 Financial statements through 30 Jun 2025 Field coverage 70% Model confidence 37%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength4/100Blend of value, momentum, and quality. Underlying universe rank 97; rank 1 is best.

Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.

Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.

Momentum10/100Medium-term price momentum. Underlying universe rank 91; rank 1 is best.

Growth91/100Revenue and earnings growth. Underlying universe rank 10; rank 1 is best.

How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E: -
Price / sales: 1.2x
EV / EBITDA: -
Free-cash-flow yield: -19.6%

Business quality

Margins and the return generated on invested capital.

Gross margin: 68.6%
Operating margin: -38.4%
Free-cash-flow margin: -22.5%
Return on invested capital: -49.8%

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth: 25.5%
EPS growth: -
Free-cash-flow growth: -
Piotroski F-score: 2/9

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield: -
Buyback yield: -17.3%
Shareholder yield: -17.3%
Net debt / EBITDA: 0.2x

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 35 relevant articles.

4 positive · 31 neutral · 0 negative

Patient CapitalFresh

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Fresh buy signal

06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.

Options expected move-Nearest-chain priced movement where available.

52-week drawdown-36.6%Distance below the 52-week high.

13-week volatility5.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

6 Feb 6 Mar 3 Apr 1 May 29 May 26 Jun 31 Jul

Weeks higher10 of 2611 weeks finished lower.

Best week+9.5%Week of 10 Jul.

Worst week-13.3%Week of 20 Mar.

Latest week+4.0%Week of 31 Jul.

Shape of recent returns

Strong gains7

Modest gains3

Flat weeks5

Modest losses2

Sharp losses9

Recent vol5.4%13-week weekly-return volatility.

Base vol6.6%52-week weekly-return volatility.

Up/down split20/20Count of positive and negative weeks in the 52-week window.

Average skew6.2% / -6.2%Average positive week versus average negative week.

07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

SectorAU Healthcare

4-week rank5 / 100

Group average-5.0%

Trend breadth23.0%

Trend23.0%active weekly trend signals

MD60.0%positive activity pressure

RS24.0%positive relative leadership

Four-week leaders

RHT · ASX45.5%AFP · ASX36.2%TTX · ASX27.4%PTX · ASX25.0%EYE · ASX23.8%

IndustryAU Medical Devices

4-week rank1 / 26

Group average-9.9%

Trend breadth19.2%

Trend19.2%active weekly trend signals

MD38.5%positive activity pressure

RS23.1%positive relative leadership

Four-week leaders

EYE · ASX23.8%OSL · ASX17.8%TRU · ASX8.3%EMV · ASX1.6%CSX · ASX1.3%

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape37/100

Trend, activity pressure, participation, and risk combine to a 37/100 tape read.

Indicator analysis11/100

Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.

Activity pressure 0.05; No reversal markers Next-Week ExpectancyNegative 38.04%

Next-week expectancy is negative with a 38.04% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors7/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 87; Small Cap Core rank 83 Patient CapitalFresh

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Fresh buy signal Sentiment52/100

Weighted news tone is neutral across 35 relevant articles.

Nova Eye Medical Ltd Revenue Breakdown – ASX:EYE Insiders50/100

No recent insider transaction evidence is stored.

Earnings50/100

No stored earnings event is currently attached to this ticker.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
31 Jul 2026	0.13 AUD	4.0%	0.14 AUD	0.17 AUD	0.40	-8.14	2.1M	Off
24 Jul 2026	0.12 AUD	4.2%	0.14 AUD	0.17 AUD	-0.05	-9.87	1.9M	Off
17 Jul 2026	0.12 AUD	4.3%	0.14 AUD	0.17 AUD	-0.59	-14.03	113.1K	Off
10 Jul 2026	0.12 AUD	9.5%	0.14 AUD	0.17 AUD	-0.91	-17.88	627.0K	Off
3 Jul 2026	0.10 AUD	0.0%	0.14 AUD	0.17 AUD	-1.07	-25.45	1.3M	Off
26 Jun 2026	0.10 AUD	-4.5%	0.14 AUD	0.17 AUD	-1.07	-25.01	125.1K	Off
19 Jun 2026	0.11 AUD	-8.3%	0.14 AUD	0.17 AUD	-1.14	-22.16	392.6K	Off
12 Jun 2026	0.12 AUD	2.1%	0.14 AUD	0.18 AUD	-1.08	-14.95	174.4K	Off
5 Jun 2026	0.12 AUD	6.8%	0.14 AUD	0.18 AUD	-1.10	-15.04	1.4M	Off
29 May 2026	0.11 AUD	-4.3%	0.14 AUD	0.18 AUD	-1.11	-21.48	208.4K	Off
22 May 2026	0.12 AUD	-8.0%	0.14 AUD	0.18 AUD	-0.99	-17.48	1.3M	Off
15 May 2026	0.12 AUD	-2.0%	0.14 AUD	0.18 AUD	-0.94	-10.14	812.5K	Off
8 May 2026	0.13 AUD	2.0%	0.14 AUD	0.18 AUD	-0.98	-9.59	1.9M	Off
1 May 2026	0.12 AUD	-7.4%	0.14 AUD	0.18 AUD	-1.08	-11.34	1.2M	Off

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.